Page 175 - 2019_01-Haematologica-web

DOT1L is a therapeutic target in myeloma
S, Maethner E, Slany RK. Misguided tran- scriptional elongation causes mixed lineage leukemia. PLoS Biol. 2009;7(11):e1000249.
26. Okada Y, Feng Q, Lin Y, et al. hDOT1L links histone methylation to leukemogenesis. Cell. 2005;121(2):167-178.
27. Krivtsov AV, Feng Z, Lemieux ME, et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell. 2008;14(5):355-368.
28. Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53-65.
29. Kim W, Kim R, Park G, Park JW, Kim JE. Deficiency of H3K79 histone methyltrans- ferase Dot1-like protein (DOT1L) inhibits cell proliferation. J Biol Chem. 2012; 287(8):5588-5599.
30. Zhang L, Deng L, Chen F, et al. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. Oncotarget. 2014;5(21):10665-10677.
31. Wong M, Tee AEL, Milazzo G, et al. The histone methyltransferase DOT1L pro- motes neuroblastoma by regulating gene
transcription. Cancer Res. 2017;77(9):2522-
2533.
32. Shaffer AL, Emre NC, Lamy L, et al. IRF4
addiction in multiple myeloma. Nature.
2008;454(7201):226-231.
33. Holien T, Vatsveen TK, Hella H, Waage A,
Sundan A. Addiction to c-MYC in multiple
myeloma. Blood. 2012;120(12):2450-2453. 34. Conery AR, Centore RC, Neiss A, et al. Bromodomain inhibition of the transcrip- tional coactivators CBP/EP300 as a thera- peutic strategy to target the IRF4 network in
multiple myeloma. Elife. 2016;5.
35. Ohguchi H, Hideshima T, Bhasin MK, et al. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016;
7:10258.
36. Suzuki H, Takatsuka S, Akashi H, et al.
Genome-wide profiling of chromatin signa- tures reveals epigenetic regulation of MicroRNA genes in colorectal cancer. Cancer Res. 2011;71(17):5646-5658.
37. Minami R, Muta K, Ilseung C, Abe Y, Nishimura J, Nawata H. Interleukin-6 sensi- tizes multiple myeloma cell lines for apopto- sis induced by interferon-alpha. Exp Hematol. 2000;28(3):244-255.
38. Zhang L, Tai YT, Ho MZG, Qiu L, Anderson KC. Interferon-alpha-based immunothera- pies in the treatment of B cell-derived hema- tologic neoplasms in today's treat-to-target era. Exp Hematol Oncol. 2017;6:20.
39. Cheon H, Borden EC, Stark GR. Interferons and their stimulated genes in the tumor microenvironment. Semin Oncol. 2014; 41(2):156-173.
40. Rosenbauer F, Waring JF, Foerster J, Wietstruk M, Philipp D, Horak I. Interferon consensus sequence binding protein and interferon regulatory factor-4/Pip form a complex that represses the expression of the interferon-stimulated gene-15 in macrophages. Blood. 1999;94(12):4274- 4281.
41. Chiappinelli KB, Strissel PL, Desrichard A, et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell. 2015;162(5):974-986.
42. Roulois D, Loo Yau H, Singhania R, et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell. 2015; 162(5):961-973.
haematologica | 2019; 104(1)
165